Camila Maringolo Ribeiro

Camila Maringolo Ribeiro

Auto-generated profile, based on publicly available information

Camila Maringolo Ribeiro

School of Pharmaceutical Sciences São Paulo State University (UNESP) Araraquara 14800-903 Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in ChemMedChem
Verified
Journal Article
Open access
GFGuilherme Fernandes
Guilherme Fernandes
KMKaryn F. Manieri
Karyn F. Manieri
ABAndressa Francielli Bonjorno
Andressa Francielli Bonjorno
DCDebora L. Campos
Debora L. Campos
CRCamila M. Ribeiro
Camila M. Ribeiro
JSJean L. Dos Santos
Jean L. Dos Santos
The emergence of multidrug‐resistant strains of M. tuberculosis has raised concerns due to the greater difficulties in patient treatment and higher mortality rates. Herein, we revisited the 2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine scaffold and identified potent new carbamate derivatives having MIC90 values of 0.18–1.63 μM against Mtb H37Rv. Compounds 47–49, 51–53, and 55 exhibited remarkable activity against a panel of clinical isolates, displaying MIC90 values below 0.5 μM. In Mtb‐infected macrophages, several compounds demonstrated a 1‐log greater reduction in mycobacterial burden than rifampicin and pretomanid. The compounds tested did not exhibit significant cytotoxicity against three cell lines or any toxicity to Galleria mellonella. Furthermore, the imidazo[2,1‐b][1,3]oxazine derivatives did not show substantial activity against other bacteria or fungi. Finally, molecular docking studies revealed that the new compounds could interact with the deazaflavin‐dependent nitroreductase (Ddn) in a similar manner to pretomanid. Collectively, our findings highlight the chemical universe of imidazo[2,1‐b][1,3]oxazines and their promising potential against MDR‐TB.

1 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PSPatricia Bento Da Silva
Patricia Bento Da Silva
VAVictor Hugo Sousa Araújo
Victor Hugo Sousa Araújo
BFBruno Fonseca-Santos
Bruno Fonseca-Santos
MSMariana Cristina Solcia
Mariana Cristina Solcia
CRCamila Maringolo Ribeiro
Camila Maringolo Ribeiro
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
The indiscriminate use of antibiotics has facilitated the growing resistance of bacteria, and this has become a serious public health problem worldwide. Several microorganisms are still resistant to multiple antibiotics and are particularly dangerous in the hospital and nursing home environment, and to patients whose care requires devices, such as ventilators and intravenous catheters. A list of twelve pathogenic genera, which especially included bacteria that were not affected by different antibiotics, was released by the World Health Organization (WHO) in 2017, and the research and development of new antibiotics against these genera has been considered a priority. The nanotechnology is a tool that offers an effective platform for altering the physicalchemical properties of different materials, thereby enabling the development of several biomedical applications. Owing to their large surface area and high reactivity, metallic particles on the nanometric scale have remarkable physical, chemical, and biological properties. Nanoparticles with sizes between 1 and 100 nm have several applications, mainly as new antimicrobial agents for the control of microorganisms. In the present review, more than 200 reports of various metallic nanoparticles, especially those containing copper, gold, platinum, silver, titanium, and zinc were analyzed with regard to their anti-bacterial activity. However, of these 200 studies, only 42 reported about trials conducted against the resistant bacteria considered a priority by the WHO. All studies are in the initial stage, and none are in the clinical phase of research.

1 June 2021 in Journal of Molecular Structure
Verified
Journal Article
Closed access
PSPaulo Victor P. dos Santos
Paulo Victor P. dos Santos
CRCamila M. Ribeiro
Camila M. Ribeiro
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
PCPedro P. Corbi
Pedro P. Corbi
FBFernando R.G. Bergamini
Fernando R.G. Bergamini
ACAlexandre Cuin
Alexandre Cuin

12 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
Nathalia AbichabkiNathalia Abichabki
Nathalia Abichabki
LZLuísa V. Zacharias
Luísa V. Zacharias
NMNatália C. Moreira
Natália C. Moreira
FBFernando Bellissimo-Rodrigues
Fernando Bellissimo-Rodrigues
Fernanda MoreiraFernanda Moreira
Fernanda Moreira
LALeonardo N. Andrade
Leonardo N. Andrade
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are a major worldwide public health problem. In the last decades, resistance to last-resort antibiotics such as polymyxin B (PB) have been increasingly observed among these superbugs, compromising the effectiveness of antimicrobial therapy. The present study aimed (i) to assess the ultrapure Cannabidiol (CBD) antibacterial activity against a broad diversity of Gram-negative (GN) and Gram-positive (GP) bacteria (44 different species, 95 strains), comprising standard strains and clinical isolates, and (ii) to investigate the antibacterial activity of the combination CBD + PB against GN bacteria, including chromosomal- and plasmid-acquired PB-resistant and intrinsically PB-resistant GNB. We evaluated CBD in vitro antibacterial activity using the standard broth microdilution method, and the antibacterial activity of the combination CBD + PB was screened using the standard broth microdilution and confirmed by checkerboard assay. CBD exhibited antibacterial activity against different GP bacterial species, lipooligosaccharide (LOS)-expressing GN diplococcus (GND) ( Neisseria gonorrhoeae , Neisseria meningitidis , and Moraxella catarrhalis ), and Mycobacterium tuberculosis . The combination CBD + PB exhibited antibacterial activity against PB-resistant GNB (e.g., Klebsiella pneumoniae ) as well as additive and/or synergistic effect against LOS-expressing GND. The antibacterial activity of the combination CBD + PB against Pseudomonas aeruginosa and plasmid-mediated colistin-resistant (MCR-1) E. coli strains could be only demonstrated in the presence of phenylalanine-arginine-β-naphthylamide (PAβN). In conclusion, our results show promising translational potential of the combination CBD + PB against MDR and XDR GNB, including PB-resistant K. pneumoniae , highlighting its potential as a rescue treatment for life-threatening infections caused by these superbugs. One Sentence Summary: Promising combination of cannabidiol (CBD) + polymyxin B (PB) against superbugs (e.g., PB-resistant Gram-negative bacilli): Repurposing CBD

27 February 2024 in Chempluschem
Verified
Journal Article
Open access
LCLucia Bonci Cavalca
Lucia Bonci Cavalca
ÚAÚlfur Á. Atlason
Úlfur Á. Atlason
ATAlexandru Trofin
Alexandru Trofin
CRCamila M. Ribeiro
Camila M. Ribeiro
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
DSDirk-Jan Scheffers
Dirk-Jan Scheffers
Citrus canker, caused by the bacterium Xanthomonas citri subsp. citri, is one of the main threats to citrus fruit production. Several phenolic compounds active against X. citri have been described in recent years. Benzene‐1,2,4‐triol is a bio‐based phenolic compound that has shown high potential as a scaffold for the synthesis of new anti‐X. citri compounds. However, benzene‐1,2,4‐triol is prone to oxidative dimerization. We evaluated the antibacterial activity of benzene‐1,2,4‐triol, its oxidized dimers, and analogous compounds. Benzene‐1,2,4‐triol has a low inhibitory concentration against X. citri (0.05 mM) and is also active against other bacterial species. Spontaneous formation of benzenetriol dimers (e. g. by contact with oxygen in aqueous solution) reduced the antimicrobial activity of benzenetriol solutions. Dimers themselves displayed lower antibacterial activity and where shown to be more stable in solution. Unlike many other phenolic compounds with anti‐X. citri activity, benzene‐1,2,4‐triol does not act by membrane permeabilization, but seems to limit the availability of iron to cells. Benzene‐1,2,4‐triol is widely recognized as toxic – our results indicate that the toxicity of benzene‐1,2,4‐triol is largely due to spontaneously formed dimers. Stabilization of benzene‐1,2,4‐triol will be required to allow the safe use of this compound.

23 March 2022 in Future Microbiology
Verified
Journal Article
Closed access
CMCamila Maringolo-Ribeiro
Camila Maringolo-Ribeiro
JGJúlia A Grecco
Júlia A Grecco
DBDébora L Bellato
Débora L Bellato
AAAryadne L Almeida
Aryadne L Almeida
VBVanessa P Baldin
Vanessa P Baldin
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Aim: Antibiotic resistance is one of the biggest threats to global health, and this study aimed better understand how the efflux pumps are related to this process in tuberculosis clinical isolates....